These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7023908)

  • 41. Does secretin-stimulated MRCP predict exocrine pancreatic insufficiency?: A comparison with noninvasive exocrine pancreatic function tests.
    Schneider AR; Hammerstingl R; Heller M; Povse N; Murzynski L; Vogl TJ; Caspary WF; Stein J
    J Clin Gastroenterol; 2006 Oct; 40(9):851-5. PubMed ID: 17016144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 13C-labeled trioctanoin breath test for exocrine pancreatic function test in patients after pancreatoduodenectomy.
    Kato H; Nakao A; Kishimoto W; Nonami T; Harada A; Hayakawa T; Takagi H
    Am J Gastroenterol; 1993 Jan; 88(1):64-9. PubMed ID: 8093586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of moderate sedation on exocrine pancreas function in normal healthy subjects: a prospective, randomized, cross-over trial using the synthetic porcine secretin stimulated Endoscopic Pancreatic Function Test (ePFT).
    Conwell DL; Zuccaro G; Purich E; Fein S; Vanlente F; Vargo J; Dumot J; O'laughlin C; Trolli P
    Am J Gastroenterol; 2005 May; 100(5):1161-6. PubMed ID: 15842594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modern imaging methods versus clinical assessment in the evaluation of hospital in-patients with suspected pancreatic disease.
    Rösch T; Schusdziarra V; Born P; Bautz W; Baumgartner M; Ulm K; Lorenz R; Allescher HD; Gerhardt P; Siewert JR; Classen M
    Am J Gastroenterol; 2000 Sep; 95(9):2261-70. PubMed ID: 11007227
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Secretin-stimulated MRCP.
    Lee NJ; Kim KW; Kim TK; Kim MH; Kim SY; Park MS; Kim AY; Ha HK; Kim PN; Lee MG
    Abdom Imaging; 2006; 31(5):575-81. PubMed ID: 16465582
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Examination of the excretory function of the pancreas with a peroral test potion].
    Günther O
    Dtsch Z Verdau Stoffwechselkr; 1965 Oct; 25(4):215-6. PubMed ID: 5888897
    [No Abstract]   [Full Text] [Related]  

  • 47. Evaluation of the Lundh test in the diagnosis of pancreatic disease.
    Levin GE; Youngs GR; Bouchier IA
    J Clin Pathol; 1972 Feb; 25(2):129-32. PubMed ID: 5017441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Limitations of faecal elastase-1 and chymotrypsin as tests of exocrine pancreatic disease in adults.
    Brydon WG; Kingstone K; Ghosh S
    Ann Clin Biochem; 2004 Jan; 41(Pt 1):78-81. PubMed ID: 14713391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Hyperamylasemia and pancreatic diseases in children].
    Krajcírová M; Cernák A; Kasanická A; Behulová D; Cierna I
    Cesk Pediatr; 1993 Nov; 48(11):648-50. PubMed ID: 7507802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new method of testing pancreatin therapy in vivo by the use of a peroral chymotrypsin substrate 4-(N-acetyl-L-tyrosyl)aminobenzoic acid.
    Fric P; Malis F; Kasafírek E; Slabý J
    Hepatogastroenterology; 1980 Jun; 27(3):220-3. PubMed ID: 6970159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The outcome of a long-term follow-up of pancreatic function after recovery from acute pancreatitis.
    Symersky T; van Hoorn B; Masclee AA
    JOP; 2006 Sep; 7(5):447-53. PubMed ID: 16998241
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipase and pancreatic amylase activities in diagnosis of acute pancreatitis in patients with hyperamylasemia.
    Yang RW; Shao ZX; Chen YY; Yin Z; Wang WJ
    Hepatobiliary Pancreat Dis Int; 2005 Nov; 4(4):600-3. PubMed ID: 16286272
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Significance of the correction of aspirated volumes for the results of the secretin-pancreozymin test (author's transl)].
    Staud R; von Kleist D; Stopik D; Hampel KE
    Z Gastroenterol; 1980 Sep; 18(9):474-7. PubMed ID: 7456565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Measurement of fecal elastase 1 by immunoreactivity: a new indirect test of the pancreatic function].
    Stein J; Schoonbroodt D; Jung M; Lembcke B; Caspary WF
    Gastroenterol Clin Biol; 1996; 20(5):424-9. PubMed ID: 8761139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Diagnosis of exocrine pancreatic malfunction with a synthetic peptide specific for chymotrypsine (author's transl)].
    Bornschein W; Goldmann FL; Dressler J
    Klin Wochenschr; 1978 Feb; 56(4):197-205. PubMed ID: 304939
    [No Abstract]   [Full Text] [Related]  

  • 56. Evaluation of the 75Se-l-selenomethionine test for pancreatic disease. Studies on gel filtration.
    Pointner H; Kletter K
    Digestion; 1980; 20(4):225-33. PubMed ID: 7390050
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Editorial: A possible new diagnostic approach in pancreatic disease (author's transl)].
    Gyr K
    Schweiz Rundsch Med Prax; 1975 Aug; 64(32):1011-2. PubMed ID: 1161746
    [No Abstract]   [Full Text] [Related]  

  • 58. Radioimmunoassay for human pancreatic chymotrypsin and measurement of serum immunoreactive chymotrypsin contents in various diseases.
    Iwaki K; Ogawa M; Tanaka S; Kosaki G
    Res Commun Chem Pathol Pharmacol; 1983 Jun; 40(3):489-96. PubMed ID: 6622821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Bedside diagnosis: keypoints in nursing and interpretation of diagnostic data. Diagnosis of the digestive system (2) - liver and exocrine pancreas function tests].
    Monna T; Shirata K; Okuda K
    Kurinikaru Sutadi; 1982 Mar; 3(3):306-15. PubMed ID: 6918695
    [No Abstract]   [Full Text] [Related]  

  • 60. [The role of the Lundh test in the diagnosis of pancreatic diseases].
    ten Thije OJ
    Ned Tijdschr Geneeskd; 1978 Aug; 122(31):1137-42. PubMed ID: 673049
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.